[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Suh SC, Jin SY, Bae SH, Kim CG, Kim JW: Retinal capillary hemangioma treated with verteporfin photodynamic therapy and intravitreal triamcinolone acetonide. Korean J Ophthalmol; 2007 Sep;21(3):178-84
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary hemangioma treated with verteporfin photodynamic therapy and intravitreal triamcinolone acetonide.
  • PURPOSE: To report a case of retinal capillary hemangioma treated with verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide.
  • Examination showed peripheral endophytic retinal capillary hemangioma, macular edema, and a best-corrected visual acuity of 20/50.
  • The hemangioma and macular edema were treated with verteporfin photodynamic therapy and intravitreal triamcinolone acetonide.
  • RESULTS: After 5 months of follow-up, involution of the hemangioma, reduction of macular edema, decrease of the feeder and draining vessel diameter, and improvement of best-corrected visual acuity to 20/25 was seen.
  • CONCLUSIONS: This verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide appeared to cause involution of the hemangioma with reduction in macular edema and improvement in visual acuity.
  • [MeSH-major] Glucocorticoids / administration & dosage. Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy. Triamcinolone Acetonide / administration & dosage
  • [MeSH-minor] Adolescent. Female. Fundus Oculi. Humans. Injections. Tomography, Optical Coherence. Ultrasonography. Vitreous Body

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1999 Oct;117(10):1329-45 [10532441.001]
  • [Cites] Can J Ophthalmol. 2005 Apr;40(2):192-4 [16049535.001]
  • [Cites] Arch Ophthalmol. 2001 Feb;119(2):232-4 [11176984.001]
  • [Cites] Arch Ophthalmol. 2001 Mar;119(3):399-404 [11231773.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):541-60 [11336929.001]
  • [Cites] Surv Ophthalmol. 2001 Sep-Oct;46(2):117-42 [11578646.001]
  • [Cites] Ophthalmology. 2001 Oct;108(10):1907-11 [11581072.001]
  • [Cites] Retina. 2002 Apr;22(2):228-32 [11927862.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2002 Jan;240(1):42-8 [11954780.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3125-30 [12202538.001]
  • [Cites] Am J Ophthalmol. 2002 Nov;134(5):788-90 [12429270.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1517-25 [12917166.001]
  • [Cites] Trans Am Ophthalmol Soc. 1970;68:367-424 [5535648.001]
  • [Cites] Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977 May-Jun;83(3 Pt 1):OP432-42 [888256.001]
  • [Cites] Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977 May-Jun;83(3 Pt 1):OP446-53 [888257.001]
  • [Cites] Can J Ophthalmol. 1986 Dec;21(7):276-83 [3801976.001]
  • [Cites] Ophthalmology. 1996 Feb;103(2):329-35 ; discussion 334-5 [8594522.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):62-3 [10691410.001]
  • (PMID = 17804927.001).
  • [ISSN] 1011-8942
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Photosensitizing Agents; 0 / Porphyrins; 0X9PA28K43 / verteporfin; F446C597KA / Triamcinolone Acetonide
  • [Other-IDs] NLM/ PMC2629681
  •  go-up   go-down


2. Sachdeva R, Dadgostar H, Kaiser PK, Sears JE, Singh AD: Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol; 2010 Dec;88(8):e334-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma.
  • PURPOSE: Single-centre consecutive interventional case series by retrospective chart review to evaluate the efficacy of verteporfin (Visudyne™) photodynamic therapy (PDT) of retinal capillary haemangioma (RCH).
  • Follow-up included documentation of best-corrected Snellen visual acuity (BCVA), tumour regression, and presence or absence of subretinal fluid (SRF) and/or lipid exudation as assessed by dilated fundus examination (DFE), fundus photos, and optical coherence tomography (OCT).
  • CONCLUSIONS: PDT is a moderately effective treatment for juxtapapillary and EP RCH.
  • The treatment benefits may be limited by pre-existing macular changes and worsening of ERM.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Retreatment. Retrospective Studies. Subretinal Fluid. Tomography, Optical Coherence. Treatment Outcome. Visual Acuity / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Acta Ophthalmologica © 2010 Acta Ophthalmologica Scandinavica Foundation.
  • (PMID = 20946329.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


3. Mennel S, Meyer CH, Callizo J: Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmol; 2010 Aug;88(5):610-3
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma.
  • OBJECTIVE: Retinal capillary haemangioma complications are characterized by progressive exudation with consecutive intraretinal and subretinal leakage.
  • A successful therapy without side-effects has not been found.
  • We report a case of retinal juxtapapillary capillary haemangioma causing consecutive leakage with macular involvement.
  • The tumour was treated with a combination of anti-vascular endothelial growth factor (VEGF) and photodynamic therapy (PDT) and was followed for 1 year.
  • METHODS: A 44-year-old woman with retinal juxtapapillary capillary haemangioma in the right eye experienced a decrease of visual acuity from 20/20 to 20/60 because of a severe leakage from the tumour involving the macula with lipid depositions.
  • Two sessions of PDT (sparing the part of the haemangioma located within the optic disc) and five injections of bevacizumab were applied in a period of 5 months.
  • Visual acuity, visual field testing, retinal thickness measurements, fundus photography and fluorescein angiography were performed to evaluate the treatment effect.
  • Retinal thickness decreased from 490 to 150 microm with the restoration of normal central macular architecture.
  • Visual field testing and angiography did not show any treatment-related vaso-occlusive side-effects.
  • CONCLUSION: In this single case, the combination of anti-VEGF and PDT appeared to be an effective strategy for the treatment of retinal juxtapapillary capillary haemangioma without side-effects.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Hemangioma, Capillary / drug therapy. Photochemotherapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Female. Fluorescein Angiography. Humans. Injections. Tomography, Optical Coherence. Visual Acuity. Vitreous Body

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222401.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


Advertisement
4. Ach T, Thiemeyer D, Hoeh AE, Schaal KB, Dithmar S: Intravitreal bevacizumab for retinal capillary haemangioma: longterm results. Acta Ophthalmol; 2010 Jun;88(4):e137-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal bevacizumab for retinal capillary haemangioma: longterm results.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Hemangioma, Capillary / drug therapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Follow-Up Studies. Humans. Injections. Retreatment. Visual Acuity / physiology. Vitreous Body. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681788.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


5. Wong YM, Jalil A, Mathews J, Stanga PE: Exudative retinal detachment following photodynamic therapy for retinal capillary hemangioma. Can J Ophthalmol; 2010 Jun;45(3):299-300
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exudative retinal detachment following photodynamic therapy for retinal capillary hemangioma.

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20436538.001).
  • [ISSN] 1715-3360
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


6. Atebara NH: Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol; 2002 Nov;134(5):788-90
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary hemangioma treated with verteporfin photodynamic therapy.
  • PURPOSE: To describe a case of exudative retinal capillary hemangioma treated with photodynamic therapy that resulted in an improvement in clinical appearance and visual acuity.
  • METHODS: A 55-year-old Asian man presented with a large exudative peripheral retinal capillary hemangioma of the left eye causing serous retinal detachment, cystoid macular edema, and a best-corrected visual acuity of 20/200.
  • The hemangioma was treated with three successive sessions of verteporfin photodynamic therapy (PDT).
  • RESULTS: With 10 months of follow-up after the initial treatment, involution of the hemangioma, reduction of subretinal fluid, and improvement of best-corrected visual acuity to 20/80 was seen.
  • CONCLUSION: Photodynamic therapy may be an effective treatment option in select cases of exudative retinal capillary hemangioma.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Exudates and Transudates. Humans. Male. Middle Aged. Retinal Detachment / etiology. Retinal Vessels / pathology. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12429270.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


7. Costa RA, Meirelles RL, Cardillo JA, Abrantes ML, Farah ME: Retinal capillary hemangioma treatment by indocyanine green-mediated photothrombosis. Am J Ophthalmol; 2003 Mar;135(3):395-8
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary hemangioma treatment by indocyanine green-mediated photothrombosis.
  • PURPOSE: To describe the clinical, angiographic and optical coherence tomography (OCT) findings of a patient with a large retinal capillary hemangioma who was treated by indocyanine green-mediated photothrombosis.
  • METHODS: An 18-year-old male patient was treated at a tertiary referral center with a novel laser-dye procedure that uses low-irradiance 810-nm laser and intravenous indocyanine green injection and was prospectively evaluated with fluorescein and indocyanine green angiography, as well as OCT.
  • Fundus photography showed marked reduction of a 3 disk diameters retinal capillary hemangioma.
  • Both fluorescein and indocyanine green angiography demonstrated reduced tumor perfusion and narrowing of the lesion feeder and draining vessels as early as 5 days after indocyanine green-mediated photothrombosis; OCT showed immediate decrease in retinal elevation and complete resolution of subretinal fluid within 2 months of treatment.
  • CONCLUSIONS: Photothrombosis using low-intensity, 810-nm light to direct laser energy continuously at the tumor after intravenous indocyanine green infusion was effective in restoring macular architecture and improving vision in a patient with a large peripheral retinal capillary hemangioma by means of substantial occlusion of the tumor vasculature and resolution of subretinal fluid.
  • [MeSH-major] Coloring Agents / therapeutic use. Hemangioma, Capillary / drug therapy. Indocyanine Green / therapeutic use. Photochemotherapy. Retinal Neoplasms / drug therapy. Retinal Vessels / drug effects
  • [MeSH-minor] Adolescent. Fluorescein Angiography. Humans. Interferometry. Light. Male. Prospective Studies. Thrombosis / etiology. Tomography. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 by Elsevier Science Inc.
  • (PMID = 12614766.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


8. Szabó A, Géhl Z, Seres A: Photodynamic (verteporfin) therapy for retinal capillary haemangioma, with monitoring of feeder and draining blood vessel diameters. Acta Ophthalmol Scand; 2005 Aug;83(4):512-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic (verteporfin) therapy for retinal capillary haemangioma, with monitoring of feeder and draining blood vessel diameters.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy. Retinal Vessels / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ophthalmologica. 1990;200(3):128-32 [2189085.001]
  • (PMID = 16029284.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


9. Bakri SJ, Sears JE, Singh AD: Transient closure of a retinal capillary hemangioma with verteporfin photodynamic therapy. Retina; 2005 Dec;25(8):1103-4
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient closure of a retinal capillary hemangioma with verteporfin photodynamic therapy.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy. Retinal Vessels / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340546.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


10. Wittenberg L, Ma P: Treatment of a von Hippel-Lindau retinal capillary hemangioma with photodynamic therapy. Can J Ophthalmol; 2008 Oct;43(5):605-6
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a von Hippel-Lindau retinal capillary hemangioma with photodynamic therapy.

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982047.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


11. Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP, Myles R: Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch Ophthalmol; 2005 Mar;123(3):328-32
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy.
  • OBJECTIVE: To investigate the efficacy of verteporfin and photodynamic therapy in the treatment of large retinal capillary hemangiomas.
  • METHODS: Case reports of 3 patients with large retinal capillary hemangiomas treated with photodynamic therapy using verteporfin.
  • Modified protocols included shorter verteporfin infusion times and longer light exposure times.
  • All cases had associated exudative retinal detachments involving the macula.
  • Cases 1 and 2 were classic endophytic retinal capillary hemangiomas.
  • Case 3 was a reactive retinal capillary hemangioma.
  • Case 1 had 2 photodynamic therapy treatments, and after 8 months, visual acuity improved to 20/40.
  • Two years after initiating photodynamic therapy, the visual acuity was 20/30 and there was no reperfusion of the hemangioma.
  • Case 2 had 3 photodynamic therapy treatments.
  • The hemangioma was fibrotic, and 20 months after initiating photodynamic therapy visual acuity improved to 20/30.
  • Case 3 had 1 treatment, 11 weeks later and visual acuity improved to 20/400.
  • Four months after treatment, visual acuity returned to counting fingers because of tractional elevation of the macula as the capillary hemangioma fibrosed.
  • Vitrectomy surgery was performed, and choroidal and retinal neovascularization was discovered.
  • In cases 1 and 2, the capillary hemangioma ultimately regressed, and the exudative detachment resolved.
  • CONCLUSIONS: Verteporfin and photodynamic therapy were effective in achieving closure of large retinal capillary hemangiomas.
  • In all cases, the hemangioma underwent fibrosis with consequent macular puckering due to retinal traction.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Female. Fibrosis. Humans. Male. Retinal Vessels / drug effects. Retinal Vessels / pathology. Treatment Outcome. Visual Acuity. Vitrectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767474.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / 5P30EY006360
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


12. Javellana JA, Drouilhet JH, Kokame GT, Chee PH, Wong BM: Retinal capillary angioma in familial exudative vitreoretinopathy treated with photodynamic therapy. Am J Ophthalmol; 2004 Apr;137(4):780-2
Genetic Alliance. consumer health - Familial exudative vitreoretinopathy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal capillary angioma in familial exudative vitreoretinopathy treated with photodynamic therapy.
  • PURPOSE: To report a case of familial exudative vitreoretinopathy with a retinal capillary angioma and persistent macular exudation treated with photodynamic therapy.
  • METHODS: A 39-year-old woman with familial exudative vitreoretinopathy presented with an intraretinal capillary angioma temporally with persistent macular exudation despite previous vitrectomy and thermal laser.
  • Photodynamic therapy to the retinal angioma was performed.
  • RESULTS: Three months after photodynamic therapy, vision was stable at 20/200 with a reduction in lesion size on B-scan ultrasonography and no leakage on fluorescein angiography.
  • CONCLUSION: Retinal capillary angioma may be present in association with familial exudative vitreoretinopathy, and photodynamic therapy may provide a good alternative treatment to decrease exudation.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Retinal Neoplasms / drug therapy. Vitreoretinopathy, Proliferative / genetics
  • [MeSH-minor] Adult. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Laser Coagulation. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Visual Acuity. Vitrectomy

  • Genetic Alliance. consumer health - Angioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15059735.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


13. Obana A, Goto Y, Ikoma M: [A case of von Hippel-Lindau disease with papillary capillary hemangioma treated by photodynamic therapy]. Nippon Ganka Gakkai Zasshi; 2004 Apr;108(4):226-32
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of von Hippel-Lindau disease with papillary capillary hemangioma treated by photodynamic therapy].
  • BACKGROUND: Laser photocoagulation of papillary hemangioma in von Hippel-Lindau disease often causes visual loss.
  • Therefore, we applied photodynamic therapy for one patient.
  • CASE: A 36-year-old male had 3.2 x 2.6 mm capillary hemangioma of the optic disc associated with a fibrovascular membrane and exudative retinal detachment involving the whole macular area in his left eye.
  • TREATMENT: Two days after the intravenous injection of 2 mg/kg of hematoporphyrin derivatives, the eye was irradiated with a dye laser of 630 nm wavelength, with irradiance of 637 mW/cm2 and a radiant exposure of 150-250 J/cm2.
  • The exudative retinal detachment and hemorrhage in the tumor increased from day 1, but the tumor and exudative changes began to resolve after 3 weeks.
  • Three years after the treatment, the tumor was completely resolved, but the patient's visual acuity was 0.1 due to atrophy of the optic nerve and pigment epithelium of the macula.
  • CONCLUSION: Although further investigation on optimal radiance avoiding damage to the optic nerve is still needed, photodynamic therapy is a promising therapeutic option for papillary hemangioma.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Optic Disk. Optic Nerve Neoplasms / drug therapy. Photochemotherapy. von Hippel-Lindau Disease / complications
  • [MeSH-minor] Adult. Hematoporphyrin Derivative / therapeutic use. Humans. Laser Therapy. Male. Retinal Detachment / etiology. Retinal Detachment / surgery. Treatment Outcome. Visual Acuity. Vitrectomy

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15148739.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 68335-15-9 / Hematoporphyrin Derivative
  •  go-up   go-down


14. Golshevsky JR, O'Day J: Photodynamic therapy in the management of juxtapapillary capillary haemangiomas. Clin Exp Ophthalmol; 2005 Oct;33(5):509-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in the management of juxtapapillary capillary haemangiomas.
  • Capillary haemangiomas occurring on or adjacent to the optic disc pose unique therapeutic problems.
  • Their natural history is highly variable, but has a propensity to lead to the development of progressive exudate with marked deterioration in visual acuity, often culminating in retinal detachment and vitreal haemorrhages.
  • On reviewing the literature, no therapeutic modality has demonstrated an efficacy in treating the lesion and providing an acceptable visual acuity result.
  • A case of a 61-year-old man with a left-sided juxtapapillary capillary haemangioma treated with verteporfin photodynamic therapy is described.
  • Subsequent treatments failed to eradicate the lesion, with visual acuity stabilizing at 6/60.
  • With larger cohorts of patients and variable treatment parameters, the true efficacy of photodynamic therapy to treat these lesions may be determined.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Optic Disk / drug effects. Optic Nerve Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Fluorescein Angiography. Humans. Male. Middle Aged. Treatment Outcome. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181278.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


15. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H: Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology; 2002 Jul;109(7):1256-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefits and complications of photodynamic therapy of papillary capillary hemangiomas.
  • OBJECTIVE: To evaluate the potential benefit and risks of photodynamic therapy (PDT) in the treatment of papillary capillary hemangioma.
  • PARTICIPANTS: Five patients with solitary capillary hemangioma on the temporal portion of the optic nerve presenting with exudative decompensation and decrease in visual acuity (VA).
  • METHODS: All eyes received a standardized PDT treatment with 6 mg/kg body surface area verteporfin and application of 100 J/cm(2) light at 692 nm.
  • A continuous follow-up was provided with documentation 1 week before and at 4 to 6 weeks, 3 months, and 12 months after the last treatment application.
  • MAIN OUTCOME MEASURES: Functional parameters included best-refracted VA (Early Treatment Diabetic Retinopathy Study), and central scanning laser ophthalmoscope (SLO) scotometry and peripheral (automated perimetry) visual fields; anatomic parameters were presence of retinal edema or serous detachment (ophthalmoscopy) and tumor size (ultrasonography).
  • Tumor regression with resolution of macular exudate and serous retinal detachment was obtained in all eyes.
  • Complications included transient decompensation of vascular permeability, occlusion of retinal vessels, and ischemia of the optic nerve.
  • Vaso-occlusive effects at the level of the retina and optic nerve compromise the functional benefit.
  • Parameters proven safe in choroidal neovascularization may be inappropriate in retinal capillary lesions of the optic nerve.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Optic Disk / blood supply. Optic Nerve Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Capillary Permeability / drug effects. Female. Fluorescein Angiography. Fundus Oculi. Humans. Male. Middle Aged. Ophthalmoscopy. Optic Neuropathy, Ischemic / chemically induced. Prospective Studies. Retinal Artery Occlusion / chemically induced. Retinal Vein Occlusion / chemically induced. Visual Acuity. Visual Fields

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12093647.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


16. Porrini G, Giovannini A, Amato G, Ioni A, Pantanetti M: Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology; 2003 Apr;110(4):674-80
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of circumscribed choroidal hemangioma.
  • PURPOSE: To evaluate the safety and effectiveness of photodynamic therapy (PDT) in the treatment of symptomatic circumscribed choroidal hemangiomas (CCH) of the posterior pole.
  • METHODS: Photodynamic therapy was applied by Zeiss laser (Visulas 6905, Carl Zeiss-Meditech AG, Jeud Germany) emitting a light at 689 nm for photosensitization and by using verteporfin (Visudyne; Novartis Ophthalmics AG, Basel, Switzerland) at a dose of 6 mg/m(2) body surface administered intravenously before treatment.
  • The diameter of the treatment spot was calculated on early frames of pretreatment indocyanine green angiography; the maximum treatment spot diameter was 6000 micro m using a Mainster wide-field lens (Ocular Instruments Inc., Bellevue, WA USA).
  • A laser beam was applied to the retina 15 minutes after the start of the infusion.
  • Two different treatment procedures were used according to the height of the lesion.
  • A radiant exposure of 100 J/cm(2) with an exposure time of 186 seconds was applied to lesions larger than 2 mm.
  • For lesions smaller than 2 mm, a radiant exposure of 75 J/cm(2) with an exposure time of 125 seconds was used.
  • No retinal pigment epithelium (RPE) changes were observed in the patients who had undergone two PDT treatments, whereas minimal alterations were detected in two of the four patients who had undergone three treatment sessions.
  • Ultrasound examination found no measurable tumor height in six (60%) cases and a marked reduction in the remaining four cases, even after one treatment (post treatment tumor height range, 0.86-1.82 mm).
  • An improvement in visual acuity (one to six lines on the Early Treatment for Diabetic Retinopathy Study chart) was observed in all the cases.
  • In all cases no damage to retinal vessels was observed.
  • CONCLUSIONS: Photodynamic therapy is a minimally invasive but effective method of treatment for CCH and may be considered as a treatment of choice, especially in patients with foveal location of the tumor.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Aged. Coloring Agents. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Prospective Studies. Safety. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12689885.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


17. Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E: Photodynamic therapy for vasoproliferative retinal tumors. Retina; 2006 Apr;26(4):404-9
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for vasoproliferative retinal tumors.
  • PURPOSE: To report our experience with photodynamic therapy (PDT) with verteporfin for patients with vasoproliferative retinal tumors (VPRTs).
  • Biomicroscopy, fluorescein angiography, indocyanine green angiography, optical coherence tomography, and ultrasonography were performed before treatment and 1 month, 3 months, 6 months, and 1 year after treatment; visual acuity was measured using Early Treatment Diabetic Retinopathy Study criteria.
  • RESULTS: At the 1-year follow-up, all tumors responded with a reduction in size (mean height: pretreatment, 2.96 mm; posttreatment, 1.32 mm), and optical coherence tomography showed complete resolution of macular exudates.
  • An improvement in visual acuity (average, 4.7 Early Treatment Diabetic Retinopathy Study letters) was observed.
  • CONCLUSION: PDT may represent an effective and safe modality of treatment for VPRTs because of its selectivity.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Coloring Agents. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Retinal Hemorrhage / diagnosis. Retinal Hemorrhage / drug therapy. Retinal Vessels / drug effects. Tomography, Optical Coherence. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603958.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


18. Dahr SS, Cusick M, Rodriguez-Coleman H, Srivastava SK, Thompson DJ, Linehan WM, Ferris FL 3rd, Chew EY: Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina; 2007 Feb;27(2):150-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina.
  • OBJECTIVE: This pilot study was designed to provide preliminary data concerning the safety and efficacy of pegylated anti-vascular endothelial growth factor (VEGF) therapy, pegaptanib, for patients with juxtapapillary or large peripheral angiomas secondary to von Hippel-Lindau (VHL) disease.
  • Secondary outcomes included changes in macular thickness, as determined by optical coherence tomography, and changes in fluorescein leakage.
  • RESULTS: Two of five patients completed the course of treatment and 1 year of follow-up.
  • These two patients had progressive decrease in retinal hard exudate and reduction in central retinal thickness measured by optical coherence tomography.
  • Lesions in the other three patients continued to progress despite treatment, and these patients did not complete the entire treatment course.
  • One patient developed a tractional retinal detachment.
  • CONCLUSIONS: Intravitreal injections of anti-VEGF therapy (pegaptanib) may decrease retinal thickening minimally and reduce retinal hard exudates in some patients with advanced VHL angiomas.
  • This finding may be related to a reduction in vasopermeability, because there was no apparent effect of treatment on the size of the primary retinal angiomas in this small pilot study.
  • [MeSH-major] Aptamers, Nucleotide / therapeutic use. Hemangioma, Capillary / drug therapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors. von Hippel-Lindau Disease / drug therapy
  • [MeSH-minor] Adult. Female. Fluorescein Angiography. Humans. Injections. Male. Middle Aged. Pilot Projects. Prospective Studies. Tomography, Optical Coherence. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290195.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 EY999999; United States / Intramural NIH HHS / / ZIE EY000487-01
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / pegaptanib
  •  go-up   go-down


19. Saldanha MJ, Edrich C: Treatment of vasoproliferative tumors with photodynamic therapy. Ophthalmic Surg Lasers Imaging; 2008 Mar-Apr;39(2):143-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of vasoproliferative tumors with photodynamic therapy.
  • The tumor was treated with one session of photodynamic therapy with 6 mg/m2 body surface area of verteporfin and a dose of 100 J/cm2 delivered in 83 seconds.
  • Photodynamic therapy is an effective treatment option in cases of exudative vasoproliferative tumors.
  • [MeSH-major] Hemangioma, Capillary / drug therapy. Photochemotherapy. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Middle Aged. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18435340.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


20. Ziemssen F, Voelker M, Inhoffen W, Bartz-Schmidt KU, Gelisken F: Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye (Lond); 2007 Aug;21(8):1125-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hemangioma, Capillary / drug therapy. Photochemotherapy. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy / methods. Humans. Middle Aged. Treatment Outcome. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545966.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


21. Toyokawa N, Kimura H, Kuroda S: Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide. Jpn J Ophthalmol; 2010 Mar;54(2):168-70
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Glucocorticoids / therapeutic use. Hemangioma, Capillary / drug therapy. Optic Nerve Neoplasms / drug therapy. Triamcinolone Acetonide / therapeutic use
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Drug Therapy, Combination. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Injections. Optic Disk. Retinal Hemorrhage / diagnosis. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vitreous Body

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2000 Dec;107(12):2240-8 [11097604.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):48-54 [10647718.001]
  • [Cites] Ophthalmology. 2002 Jul;109 (7):1256-66 [12093647.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):1015-22 [9402176.001]
  • [Cites] Retina. 2007 Feb;27(2):150-8 [17290195.001]
  • (PMID = 20401570.001).
  • [ISSN] 1613-2246
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glucocorticoids; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; F446C597KA / Triamcinolone Acetonide
  •  go-up   go-down


22. Walker RA, Colleaux KM: Preretinal neovascularization after bevacizumab injections in a patient with von Hippel-Lindau syndrome. Can J Ophthalmol; 2009 Oct;44(5):608-9
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preretinal neovascularization after bevacizumab injections in a patient with von Hippel-Lindau syndrome.

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789606.001).
  • [ISSN] 1715-3360
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


23. von Buelow M, Pape S, Hoerauf H: Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol Scand; 2007 Feb;85(1):114-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hemangioma, Capillary / drug therapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244223.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


24. Barbezetto IA, Smith RT: Vasoproliferative tumor of the retima treated with PDT. Retina; 2003 Aug;23(4):565-7
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hemangioma, Capillary / drug therapy. Photochemotherapy. Porphyrins / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Fluorescein Angiography. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12972778.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down






Advertisement